Updates ·
Health notices · Tuesday 11 August
3 notices from the agencies today, in plain words, each with the original linked.
Taylor Fresh Foods recalls jalapeno-containing products over possible Salmonella risk
Centers for Disease Control and Prevention (CDC) · Food safety
If you have bought Taylor Fresh Foods finished products containing jalapeños, this CDC notice says those items are being recalled because they may be contaminated with Salmonella.
Salmonella is an organism that can cause illness. If you have the recalled products, the recall means the situation has changed since before you saw this notice.
Cetirizine tablets recalled due to possible ranitidine cross contamination
FDA-SAFETY
If you have cetirizine hydrochloride tablets (5 mg) from Unique Pharmaceutical Laboratories, the company has issued a voluntary nationwide recall after finding potential cross contamination with ranitidine, a different medicine.
Cross contamination means some ranitidine could have mixed with the cetirizine tablets during manufacturing. This recall is intended to prevent people from taking potentially affected tablets.
When and where: the recall is being carried out nationwide in the US, and it was issued on July 18, 2026, in Panoli, Gujarat.
FDA granted accelerated approval for engineered viral therapy in melanoma
Food and Drug Administration (FDA) · Announcement
If you have advanced, refractory melanoma, the FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg).
Tudriqev is a genetically modified oncolytic viral therapy, meaning it uses an engineered virus to treat cancer.
What changes for you: this therapy now has FDA accelerated approval for advanced, refractory melanoma, so it may be part of future treatment options where offered.
Where this comes from
- Taylor Fresh Foods recalls jalapeno-containing products over possible Salmonella riskCDC — food safety
- Cetirizine tablets recalled due to possible ranitidine cross contaminationfda-safety
- FDA granted accelerated approval for engineered viral therapy in melanomafda-press
Each notice above is summarised from the agency's own publication, linked beside it. Nothing here is a finding of ours.